Drugs / ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01982487 | Dec 2013 → Sep 2017 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01982487 ↗ |
| Modality | Vaccine | “ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine” NCT01982487 ↗ |
| Route | Subcutaneous | “Given SC” NCT01982487 ↗ |